|Assessment Status||Rapid Review Complete|
|Indication||Is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.|
|Rapid review commissioned||08/03/2022|
|Rapid review completed||15/03/2022|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that Nirmatrelvir/Ritonavir (Paxlovid®) not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.